AbbVie Inc.: CEO History

The spin-off was not an act of corporate weakness. In oncology, AbbVie's competitive challenges are more acute. The most structurally significant challenge remains the ongoing erosion of Humira revenues in the United States. A second persistent challenge is the regulatory and safety scrutiny surrounding Rinvoq and the broader class of JAK inhibitors.

The U.S. Food and Drug Administration in 2021 required all JAK inhibitors — including Pfizer's Xeljanz, Eli Lilly's Olumiant, and AbbVie's Rinvoq — to carry enhanced Black Box warning labels following a post-marketing safety study that showed elevated risks of serious cardiovascular events, blood clots, cancer, and death in certain patient populations. These warnings have complicated prescriber adoption of Rinvoq, particularly in rheumatoid arthritis where patients have existing cardiovascular risk factors. AbbVie has worked to differentiate Rinvoq's safety profile through clinical data, and the drug has gained traction in indications like atopic dermatitis and inflammatory bowel disease where the patient population is younger and cardiovascular risk is lower, but the label restrictions remain a real commercial constraint. Pipeline concentration risk in neuroscience and late-stage oncology programs represents a fourth area of concern.